检索规则说明:AND代表“并且”;OR代表“或者”;NOT代表“不包含”;(注意必须大写,运算符两边需空一格)
检 索 范 例 :范例一: (K=图书馆学 OR K=情报学) AND A=范并思 范例二:J=计算机应用与软件 AND (U=C++ OR U=Basic) NOT M=Visual
作 者:李增鹏[1] 向德兵[1] 张沁宏[1] 仲召阳[1] 肖华亮[1] 牟江洪[1] 王东[1]
机构地区:[1]第三军医大学大坪医院野战外科研究所病理科,重庆400042
出 处:《重庆医学》2007年第19期1924-1925,F0003,F0002,共4页Chongqing medicine
基 金:国家自然科学基金(30100228);重庆市科委应用基础基金(20016824)。
摘 要:目的探讨DNA修复基因脱嘌呤/脱嘧啶核酸内切酶(apurinic/apyrimidinic endonuclease 1,APE1)在大肠癌发生、发展中的作用。方法应用免疫组化PowerVision^(TM)法检测125例大肠癌、72例大肠腺瘤、60例癌旁大肠黏膜和40例正常大肠黏膜中APE1的表达和细胞定位,并分析其与大肠癌临床病理之间的关系。结果正常大肠黏膜APE1呈胞核表达,大肠腺瘤和大肠癌组织APE1表达特征发生改变,呈胞核表达、单纯胞浆表达或核浆共同表达,大肠癌组织APE1胞浆异位表达率为73.6%,大肠腺瘤APE1胞浆异位表达率为83.3%,二者差异无统计学意义(P>0.05),但均显著高于癌旁大肠黏膜(10%)和正常大肠黏膜(0)(P<0.01)。APE1胞浆异位表达与大肠癌临床分期和淋巴结转移有关(P<0.01、P<0.05)。结论APE1胞浆异位表达可能在大肠癌的发生、发展中起重要作用。Objective To investigate the role of apurimidinic endonuclease 1 (APE1) in the carcinogenesis and progression of colorectal carcinoma (CRC). Methods Expression of APE1 was examined by PowerVisionTM immunohistochemical technique in 40 cases of normal colorectal mucosa, 60 cases of adjacent colorectal mucosa with CRC, 72 cases of colorectal adenoma and 125 cases of colorectal carcinoma. Results In normal colorectal mucosa, APE1 was detected in nucleus of epithelial cells, the shifts of APE1 from nucleus to cytoplasm was observed in 6 of 60 (10%) adjacent colorectal mueosa tissues. The shifts of APE1 from nucleus to cytoplasm was observed in 92 of 125 (73.6%) CRC tissues and 60 of 72 (83. 3%) colorectal adenoma,which was significantly higher than that of normal colorectal mucosa and adjacent colorectal mucosa tissues with CRC(P〈0.01). Statistic analysis showed that the shifts of APE1 from nucleus to cytoplasm was associated with Dukes stage and lymph node metastasis in CRC(P〈0.01,P 〈0.05). Conclusion The shifts of APE1 from nucleus to cytoplasm might play a pivotal role in the carcinogenesis and progression of colorectal carcinoma.
关 键 词:脱嘌呤/脱嘧啶核酸内切酶 氧化还原因子-1 大肠癌
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在载入数据...
正在链接到云南高校图书馆文献保障联盟下载...
云南高校图书馆联盟文献共享服务平台 版权所有©
您的IP:216.73.216.249